In particular, differential diagnosis of cardiac amyloidosis (CA) is critical for effective management: light-chain cardiac amyloidosis (AL-CA) is a hematologic malignancy that requires cytotoxic chemotherapy and/or stem cell transplantation, whereas transthyretin CA (TTR-CA) is a rare infiltrative cardiomyopathy that requires specific treatments such as TTR stabilization [4]. This evidence concerns the gene TTR and cardiac amyloidosis.